Quick Answer
VACCINEX, INC. reported Total Assets of $2.60 million for the year ending 2024.
- VACCINEX, INC. showed a decrease of -28.5% in Total Assets from 2023 to 2024.
- This data is from VACCINEX, INC.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2017 to 2024 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $4.72 million | Q3 2018: $29.88 million | Q1 2019: $13.29 million | Q2 2019: $7.12 million | Q3 2019: $10.81 million | Q1 2020: $4.88 million | Q2 2020: $3.10 million | Q3 2020: $18.73 million | Q1 2021: $30.68 million | Q2 2021: $23.79 million | Q3 2021: $15.19 million | Q1 2022: $18.12 million | Q2 2022: $12.57 million | Q3 2022: $8.61 million | Q1 2023: $4.90 million | Q2 2023: $3.09 million | Q3 2023: $2.56 million | Q1 2024: $7.37 million | Q2 2024: $2.37 million | Q3 2024: $4.85 million.
- Over the full 8 years of available data (2017 to 2024), VACCINEX, INC.'s Total Assets has declined by 53.4%.
- Historical annual values: Fiscal year 2024: $2.60 million | Fiscal year 2023: $3.63 million | Fiscal year 2022: $7.98 million | Fiscal year 2021: $9.84 million | Fiscal year 2020: $11.70 million | Fiscal year 2019: $4.60 million | Fiscal year 2018: $22.03 million | Fiscal year 2017: $5.58 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: